...of the Swiss Biotech Association since 2013 and previously founded and led Swiss antibody play ESBATech AG...

...expects to launch brolucizumab this year and gained the mAb via its 2009 acquisition of ESBATech AG...

...positions in Basel. The pharma plans to close a biologics group in Shanghai and its ESBATech AG...

...said. The pharma plans to close a biologics group in Shanghai, as well as its ESBATech AG...

...of Alcon Inc. Alcon gained ophthalmic rights to the product through its 2009 acquisition of ESBATech AG...

...So there are both early and late-stage opportunities. And in between there are things like ESBATech."...
...the T-Spot.TB test for tuberculosis. In September 2009, Alcon Inc. acquired the ophthalmic applications of ESBATech AG...
...Crucell N.V. Johnson & Johnson (NYSE:JNJ) $2,400 2008 Speedel Novartis AG (NYSE:NVS; SIX:NOVN) $1,000 2009 ESBATech AG...

...Thomas Dyrberg will join Delenex's board. Delenex was spun out of EsbaTech AG in 2009 when EsbaTech...

...OctoPlus will develop a controlled-release formulation of an undisclosed biologic from Alcon's ESBATech AG research unit for...
...its PolyActive drug delivery technology. OctoPlus is responsible for preclinical testing and process development, while ESBATech...

...exit after 11 years and $72 million in investment. The company is a spinout from ESBATech AG...
...and a lead candidate that's already shown proof of concept, albeit in a different indication. ESBATech...
...21, 2009) . Following the deal, the investors spun out Delenex with exclusive rights to ESBATech's...

...HBM BioVentures; BioMedInvest; and VI Partners. Delenex was spun out of EsbaTech AG in 2009 when EsbaTech...